AT&T Misses on Revenue from Cheaper Tablet Data Fees

Michael Teague |

AT&T Misses on Revenue from Cheaper Tablet Data FeesAT&T (T) reported net income for the first quarter of $3.7 billion, or $0.67 per share on revenue of $31.36 billion.

Adjusted earnings, excluding the sale of an advertising business, were at $0.64 per share, above the $0.60 earned in the prior-year period, and exactly what analysts had predicted.

Revenue, however, was nearly half a billion less than analyst expectations of $31.74 billion, and less than the prior year period when the company brought it $31.82 billion.



The company added 296,000 devices to contract-based plans, but all in the form of tablets carrying lower monthly fees. Overall, the AT&T posted its first ever loss on contract-based plans, and, excluding tablets, lost contract-based devices to the tune of 69,000.

This created a situation in which average revenue per contract user rose only 0.9 percent for Q1.

Company CFO John Stephens recognized the role of tablets in the decrease in spending for the period, noting that the company’s cheap data plans for the devices are not set in stone. “We put that in place to see how it would work, to stimulate demand,” but later in the conference call said that it was not necessarily a “permanent offering.”

The company’s shares closed regular trading at $39 on a slight gain of 0.7 percent, but slipped 1.54 in afterhours to $38.40.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
GPAC Global Partner Acquisition Corp. 9.95 0.00 0.00 0 Trade
T AT&T Inc. 40.16 0.22 0.55 11,309,929 Trade

Comments

Emerging Growth

Naked Brand Group Inc

Naked Brand Group Inc through its wholly-owned subsidiary is engaged in manufacturing and selling of direct and wholesale men's undergarments to consumers and retailers.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…